Carlos Dzik

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 627 citations · Full text

First-line Therapy, Urology, Chemotherapy Versus Chemotherapy +7

IDH1 mutations in a Brazilian series of Glioblastoma

Miyuki Uno, Sueli Mieko Oba‐Shinjo, Roseli da Silva et al. · Clinics · 2011 · 30 citations · Full text

Renal Medullary Carcinoma Response to Chemotherapy: a Referral Center Experience in Brazil

Marina Cavalcanti Maroja Silvino, Camila Motta Venchiarutti Moniz, Gustavo Henrique Munhoz Piotto et al. · Rare Tumors · 2013 · 28 citations · Full text

Urology, Surgical Oncology, Genitourinary Cancer +13

Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer

Romualdo Barroso‐Sousa, Leonardo Gomes da Fonseca, Karla Teixeira Souza et al. · Medical Oncology · 2014 · 18 citations

Metronomic Oral Cyclophosphamide, Urology, Medicine +8

Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.

Diogo Assed Bastos, Carlos Dzik, Dana E. Rathkopf et al. · PubMed · 2014 · 18 citations

Androgen Receptor, Urology, Genitourinary Cancer +11